IJCRT.ORG ISSN : 2320-2882

INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Review On Nipah Virus

[1]Tarun Kumar, [2]Shalu Dhiman, [3]Dr.Jyoti Gupta,[4] Raman Gupta,[5]Yashsavi Bali

[1]B.Pharmacy 8th semester student, [2]Assistant Professor, IEC School of Pharmacy [3]HOD&Profeesor , IEC School of Pharmacy,[4]Assistant Professor,IEC School of Pharmacy,[5]Assistant Professor,IEC School of Pharmacy

[1]IEC School of Pharmacy, IEC University,

[1]IEC University, Baddi, solan, Himachal Pradesh, 174103

Abstract

Nipah contagion(NiV) is a largely pathogenic zoonotic paramyxovirus that's a member of the family * Paramyxoviridae * and rubric * Henipavirus *. First linked during an outbreak in Malaysia in 1998 – 1999, Nipah contagion has ago caused repeated outbreaks in South and Southeast Asia, particularly in Bangladesh and India. The contagion is naturally harboured by fruit batons of the rubric * Pteropus *, which act as force hosts and transmit the contagion to humans either directly or through intermediate hosts similar as gormandizers or via defiled food sources. There have also been reports of mortal- to-mortal transmission, particularly in homes and healthcare installations. Clinically, Nipah contagion infections can beget anything from mild fever and no symptoms to severe encephalitis and acute respiratory torture, with case casualty rates ranging from 40 to further than 75. Viral entry through ephrin- B2 and ephrin- B3 receptors is part of the pathogenesis, which results in expansive endothelial infection, vasculitis, and involvement of the central nervous system. Treatment for Nipah contagion infection is still substantially probative as there's presently no approved vaccine or specific antiviral drug. nevertheless, preclinical exploration on monoclonal antibodies and experimental antivirals has produced encouraging issues. The World Health Organisation has designated the Nipah contagion as a precedence pathogen with epidemic eventuality due to its high mortality, eventuality for person- to-person transmission, and lack of effective treatment. To stop unborn outbreaks and lessen their impact on public health, it's essential to ameliorate surveillance, early opinion, infection control strategies, and public mindfulness.

Keywords- Nipah virus (NiV),Henipavirus , Zoonotic transmission , Pteropus fruit bats (reservoir host) ,Acute encephalitis syndrome,High case fatality rate & epidemic potential

INTRODUCTION

Due to its high mortality rate, eventuality for mortal- to- mortal transmission, and lack of approved vaccines or specific antiviral remedy, the largely pathogenic zoonotic contagion known as Nipah contagion(NiV) has come a major public health concern(1).

The contagion was first linked during an outbreak of acute encephalitis among gormandizer growers in Malaysia and Singapore between 1998 and 1999. The Nipah contagion is an enveloped, negativesense, single- stranded RNA contagion that's a member of the rubric Henipavirus within the family Paramyxoviridae(2). It was originally discovered during an acute encephalitis outbreak among gormandizer growers in Malaysia and Singapore in 1998 and 1999.

According to epidemiological studies, gormandizers are intermediate amplifying hosts that grease batto- mortal transmission and beget significant morbidity, mortality, and profitable dislocation(3).

The Nipah contagion's natural force hosts are fruit batons of the rubric Pteropus(4).

These batons exfoliate the contagion in their faeces, urine, and slaver while remaining asymptomatic. mortal infection occurs through multiple transmission routes, including direct contact with infected batons, consumption of food products defiled by club concealment most specially raw date win tire — exposure to infected domestic creatures, and person- to- person transmission(5).

The contagion's capability to sustain transmission chains has been stressed by intermittent outbreaks in Bangladesh and India, which have shown effective mortal- to- mortal transmission, especially in ménage and healthcare settings(6).

Clinical instantiations of Nipah contagion infection range extensively in inflexibility, from acute respiratory torture and severe encephalitis to mild fever(6,7).

generally lasting four to fourteen days, the incubation period can occasionally go longer. Fever, headache, myalgia, and puking are exemplifications of earlynon-specific symptoms that can snappily develop into altered internal status, seizures, coma, and death(7).

The Nipah contagion continues to pose a serious trouble to the security of global health due to its zoonotic origin, ecological motorists, and implicit for afflictions. To reduce the threat of unborn outbreaks, surveillance systems must be strengthened, infection control procedures must be bettered, and effective vaccines and treatments must be developed more snappily(8).

Direct contact with infected batons, eating food tainted with club concealment(most specially raw date win tire), or coming into contact with infected domestic creatures like gormandizers can all affect in mortal infection(9,10).

There have been reports of late- onset or returning encephalitis, and survivors may have longterm neurological consequences(11).

Historical Background of NIV

Howard Long, whose advocacy in the 1950s emphasised the need for a interpretation that combined delicacy and readability, is constantly credited with having the first idea for a ultramodern English Bible restatement(12).

During the 1960s, these worries gained traction among evangelical academics and religious authorities, sparking sanctioned exchanges about creating a new restatement(13).

Hosts and Budgets

Although some mortal- to- mortal transmission has been proved, particularly in family and healthcare settings, humans are incidental and dead- end hosts(14).

Compared to batons and gormandizers, domestic creatures like nags, pussycats, tykes , and scapegoats have demonstrated serological substantiation of infection, but their donation to long- term transmission is allowed to be minimum(15).

The first reports of NiV spillover from batons to intermediate beast hosts, especially gormandizers, were made during the 1998 – 1999 outbreak in Malaysia, where gormandizers served as amplifying hosts and allowed for wide mortal transmission through close contact(16,17).

Epidemiology

The largely pathogenic zoonotic contagion known as Nipah contagion(NiV) is a member of the rubric Henipavirus(family Paramyxoviridae) and causes occasional outbreaks of respiratory illness and severe encephalitis in humans, substantially in South and Southeast Asia(18,19).

Over 265 mortal cases and a case casualty rate of about 40 redounded from the first given outbreak, which took place in Malaysia and Singapore in 1998 – 1999 and was primarily transmitted from infected gormandizers to humans(20,21).

Following this, intermittent outbreaks have been reported nearly annually in Bangladesh since 2001 and periodically in India, particularly in West Bengal and Kerala, with advanced case casualty rates ranging from 40 to 75(22,24).

The maturity of outbreaks were linked to both significant mortal- to- mortal transmission, particularly among caregivers and healthcare workers, and direct club- to- mortal transmission through consumption of raw date win tire defiled by Pteropus club concealment, according to epidemiological studies conducted in Bangladesh and India(25,28).

Nipah is veritably seasonal; outbreaks generally do in the downtime, from December to May, when club viral slipping is at its peak and date win tire is gathered(29, 30).

NiV is extensively circulated among fruit club populations throughout Asia, including Thailand, Cambodia, Indonesia, and the Philippines, according to surveillance studies, suggesting a wide geographic distribution and ongoing spillover threat(31, 33).

High mortality and outbreak modification are also caused by socioeconomic factors like close mortal-beast contact, traditional eating habits, shy healthcare structure, and delayed opinion(34, 35).

The World Health Organisation has designated NiV as a precedence pathogen because of its high mortality rate, eventuality for pandemics, and trouble to public health in the absence of approved vaccines or targeted antiviral remedy(36, 37).

Beast Budgets

The main natural beast budgets of the Nipah contagion(NiV) are fruit batons of the rubric Pteropus(family Pteropodidae), which sustain the contagion in the wild without flaunting clinical symptoms(38,40).

multitudinous serological and molecular examinations have verified the presence of NiV antibodies, viral RNA, and live contagion in Pteropus batons across South and Southeast Asia, including Malaysia, Bangladesh, India, Thailand, and Cambodia, demonstrating wide and patient rotation of the contagion in club populations(41,43).

These batons' long lifetime, gregarious roosting habits, wide migrant and rustling ranges, and sporadic viral slipping through slaver, urine, and feces especially during times of physiological stress like breeding or food failure each contribute to their force capability(44).

Spillover from batons to other creatures occurs substantially through impurity of fruits, beast feed, or win tire, leading to infection of intermediate or amplifying hosts(45).

During the Malaysian outbreak of 1998 – 1999, gormandizers played a major part as amplifying hosts, acquiring infection from club- defiled fruit and latterly transmitting the contagion efficiently to humans, although gormandizers are n't considered true budgets due to the lack of longterm viral conservation(46).

Other domestic creatures, including nags, tykes , pussycats, and scapegoats, have also shown serological substantiation of NiV exposure; still, these creatures are considered incidental hosts rather than budgets(47).

Pteropus fruit batons are the only known natural budgets of the Nipah contagion, according to the maturity of available data, pressing their pivotal part in the ecology and zoonotic spread of the illness.

Transmission of Nipah Virus

The Nipah contagion(NiV) is a serious public health concern due to its complicated transmission, which includes limited mortal- to- mortal transmission, intermediate beast modification, and zoonotic spillover(48, 49).

Fruit batons of the rubric Pteropus sustain the natural transmission cycle by periodically excreting the contagion in their slaver, urine, faeces, and incompletely consumed fruits without passing any symptoms(50,52).

Primary zoonotic transmission to humans can be directly through contact with infected creatures or laterally through impurity of food sources(53).

NiV was spread from batons to gormandizers during the first outbreak in Malaysia in 1998 – 1999 when fruit defiled by batons was dropped into gormandizer enclosures. gormandizers also served as amplifying hosts, effectively spreading the contagion to humans through close contact, respiratory concealment, and contact with fleshly fluids(54,56).

On the other hand, outbreaks in Bangladesh and India have primarily involved direct club- tohuman transmission, particularly through ingestion of raw date win tire tainted with club urine or slaver, which is a culturally significant practice in these areas(57,59).

Person- to- person transmission through close contact with respiratory driblets, fleshly fluids, or defiled fomites from infected cases has been considerably proved in Bangladesh and India, especially among family caregivers and healthcare workers(60,62).

In healthcare surroundings with inadequate infection control procedures, nosocomial transmission has contributed to the modification of outbreaks(63).

Epidemiological substantiation suggests that NiV transmission is seasonal, coinciding with increased viral slipping in batons and mortal exposure during downtime months(64).

Indeed though there's substantiation of infection in other domestic creatures like nags, pussycats, tykes , and scapegoats, their donation to long- term transmission is minimum, and they're regarded as incidental hosts(65).

Overall, the spread of the Nipah contagion highlights the significance of a One Health approach for forestallment and control by demonstrating a strong commerce between ecological factors, mortal geste , and healthcare practices(66,67).

Pathogenesis of Nipah Virus

High mortality rates are caused by the pathogenesis of Nipah contagion(NiV) infection, which includes a series of viral entries, systemic dispersion, endothelial damage, and severe neurological and respiratory damage(68,69).

Infection generally begins after exposure to contagious respiratory driblets, defiled food, or body fluids, allowing the contagion to enter through the respiratory epithelium or oropharyngeal mucosa and replicate locally before spreading to indigenous lymph bumps and the bloodstream(70,71).

Because NiV interacts with ephrin- B2 and ephrin- B3 receptors, which are largely expressed in vascular endothelium, the central nervous system, and respiratory apkins, it has a strong affinity for endothelial cells and neurones(72,74).

wide vasculitis, endothelial syncytium conformation, thrombosis, and vascular leakage are caused by viral replication in endothelial cells, which results in ischaemic injury and bleeding in several organs, including the brain, lungs, and spleen(75,77).

Acute encephalitis, seizures, and coma are clinical instantiations of neuronal infection, inflammation, and necrosis caused by haematogenous spread or dislocation of the blood – brain hedge(78,79).

Necrotising vasculitis, microinfarctions, perivascular inflammation, and multinucleated giant cells have all been shown in affected brain towel by histopathological examinations(80,81).

Alveolar epithelium and pulmonary endothelium infection, which causes interstitial pneumonia, acute respiratory torture, and increased viral slipping that increases transmissibility, are characteristics of pulmonary involvement(82,83).

The host vulnerable response plays a binary part, as shy early interferon responses permit unbounded viral replication, while inordinate cytokine release contributes to immunopathology and complaint inflexibility(84,85).

Months or times after the original infection, some survivors may witness delayed or returning encephalitis due to the contagion's continuity within neural apkins(86).

NiV's severe clinical course and epidemic eventuality are explained by a combination of immunemediated towel damage, vascular dysfunction, and viral cytopathic goods(87).

Treatment of Nipah Virus Infection

As of right now, Nipah contagion(NiV) infection can not be treated with a licenced, targeted antiviral drug; rather, operation is substantially dependent on ferocious probative care with the thing of lowering morbidity and mortality(88,89).

Cases constantly develop fleetly progressive encephalitis and severe respiratory torture taking advanced medical support, so early opinion and prompt hospitalisation are essential(90).

Maintaining breathing, rotation, and airway, managing elevated intracranial pressure, controlling seizures, correcting fluid and electrolyte imbalances, and furnishing mechanical ventilation for respiratory failure are all exemplifications of probative care(91,92).

Although ribavirin, a broad- diapason antiviral drug, was used empirically during the Malaysian outbreak and was linked to lower mortality in experimental studies, its(93, 95). eness is still unknown because randomised controlled trials have n't been conducted(93,95).

transnational health organisations presently advise against the routine use of ribavirin due to its limited and inconsistent antiviral exertion against NiV, as demonstrated by posterior in vitro and beast studies(96).

An overview of drugs that may have antiviral properties against the Nipah virus

Drug / Agent	Drug Class / Type	Proposed Mechanism of Action	Evidence Level	Key Findings	References
Ribavirin	Nucleoside analogue	Inhibits viral RNA synthesis	In vitro, observational human data	Reduced mortality suggested in Malaysian outbreak; efficacy unconfirmed	[97,98]
Favipiravir (T-705)	RNA polymerase inhibitor	Inhibits viral RNA-dependent RNA polymerase	Animal models (hamster)	Improved survival when administered early	[99,100]
Remdesivir (GS-5734)	Nucleotide analogue	Premature termination of viral RNA transcription	In vitro, animal models	Potent inhibition of henipavirus replication	[101,102]
m102.4 monoclonal antibody	Human monoclonal antibody	Blocks G glycoprotein–ephrin receptor binding	Animal models, compassionate human use	Complete protection in non-human primates	[103,104]
Chloroquine	Antimalarial	Interferes with endosomal pH and viral entry	In vitro	Limited inhibition; not effective in vivo	[105]
Interferon-α / β	Immunomodulator	Enhances antiviral host response	In vitro	Partial suppression of viral replication	[106]
Fusion-inhibitory peptides	Entry inhibitors	Prevent fusion of viral and host membranes	In vitro	Strong inhibition of viral entry	[107]

Drug / Agent	Drug Class / Type	Proposed Mechanism of Action	Evidence Level	Key Findings	References
Griffithsin	Lectin protein	Binds viral glycoproteins	In vitro	Broad antiviral activity including paramyxoviruses	[108]
Small-molecule entry inhibitors	Experimental antivirals	Block virus–receptor interaction	In vitro	Reduced viral infectivity	[109]
Convalescent plasma	Passive immunotherapy	Provides neutralizing antibodies	Experimental / limited use	Theoretical benefit; limited evidence	[110]

Prevention and Control of Nipah Virus

Since there's presently no approved vaccine or targeted antiviral treatment, forestallment and control of Nipah contagion(NiV) infection primarily depend on lowering zoonotic spillover, stopping mortal- to- mortal transmission, and bolstering public health preparedness(111,112).

preventative measures concentrate on minimising impurity of tire collection spots because fruit batons of the rubric Pteropus are the natural budgets(113,115).

It has been demonstrated that public mindfulness juggernauts that emphasise safe eating habits, avoiding incompletely consumed fruits, and minimising contact with sick or dead creatures greatly reduce the threat of spillover in aboriginal areas(116).

Advanced ranch biosecurity practices, keeping beast down from fruit trees, and covering for beast illness are essential for precluding outbreaks in surroundings where domestic creatures like gormandizers serve as amplifying hosts(117,118).

Important rudiments of outbreak control include early case discovery through bettered surveillance systems, quick laboratory opinion, and prompt insulation of suspected cases(119).

Strict infection forestallment and control measures in healthcare settings, similar as the use of particular defensive outfit, hand hygiene, safe running of patient concealment, and applicable waste operation, can effectively reduce mortal- to- mortal transmission(120,121).

During outbreaks, community- position monitoring, contact dogging, and quarantining exposed individualities are pivotal in dismembering transmission chains(122).

In resource- constrained surroundings where nosocomial transmission has been current, training healthcare labor force and guaranteeing the vacuity of sufficient infection control structure are especially pivotal(123).

NiV has been designated as a high- trouble pathogen by the World Health Organisation and other organisations on a global scale, pressing the necessity of coordinated One Health approaches that integrate the environmental, beast, and mortal health sectors(124).

Long- term Nipah contagion complaint forestallment and control depend on ongoing exploration into vaccines, monoclonal antibodies, and antiviral medicines as well as indigenous and global cooperation(125).

Opinion of Nipah Virus Infection

Nipah contagion(NiV) infection is delicate to diagnose because of its nonspecific early clinical donation and the demand for high- constraint laboratory installations, but prompt and precise opinion is essential for patient care and outbreak control(126,127).

Clinically, cases who present with acute fever and neurological symptoms like encephalitis or severe respiratory torture should be suspected of having a NiV infection.

especially in people who have preliminarily come into contact with infected creatures, batons, or verified mortal cases in aboriginal areas(128,129).

The main system used for laboratory evidence is real- time rear recap polymerase chain response(RT-PCR), which is regarded as the gold standard and can be used on clinical samples similar as blood, urine, cerebrospinal fluid, throat and nasal hearties, and cerebrospinal fluid during the acute phase of illness(130 – 132).

Because of NiV's high pathogenicity, contagion insulation in cell culture, which offers conclusive evidence of infection, is only done in biosafety position- 4(BSL- 4) laboratories and is n't constantly carried out(133).

Enzyme- linked immunosorbent assay(ELISA) is used to descry NiV-specific IgM and IgG antibodies, indicating recent or former infection(134,135). Serological tests are pivotal in opinion, particularly during the convalescent phase.

Although neutralisation assays have a high particularity, they're substantially only used in reference labs(136).

Immunohistochemistry can be employed in fatal cases to descry viral antigens in towel samples, particularly brain and lung apkins, furnishing precious pathological evidence(137).

Multiple small cortical and subcortical lesions suggestive of viral encephalitis are among the characteristic findings revealed by imaging ways like glamorous resonance imaging(MRI) that constantly support opinion(138).

opinion is nearly linked to epidemiological exploration, contact dogging, and public health surveillance systems due to the eventuality for NiV outbreaks(139).

Effective NiV opinion and outbreak response depend on strengthening laboratory capacity, standardising individual procedures, and guaranteeing prompt reporting(140).

Conclusion

Because of its high case casualty rate, broad host range, and capacity to beget intermittent outbreaks with epidemic eventuality, the Nipah contagion(NiV) continues to be one of the most dangerous arising zoonotic pathogens(141,142).

Fruit batons of the rubric Pteropus are the natural hosts of the contagion, which can spread to humans through defiled food, infected intermediate hosts, or direct mortal- to- mortal contact, especially in homes and healthcare installations(143,145).

intermittent outbreaks in South and Southeast Asia demonstrate how ecological disturbance, shifting land use, and customary mortal geste

have a significant impact on the emergence of complaint(146,147).

Acute encephalitis and respiratory failure are common symptoms of the severe clinical course of NiV infection, which is aggravated by difficulties in early opinion and confined access to high- constraint laboratory installations in aboriginal areas(148,149).

Monoclonal antibodies and experimental antivirals are still being delved , and treatment options are still generally probative despite advances in our understanding of viral pathogenesis and transmission dynamics(150,151).

Reference and Bibliography

[1] World Health Organization. Nipah virus [Internet]. Geneva: WHO; 2023 [cited 2026 Jan 28].

[2] Centers for Disease Control and Prevention. Nipah virus (NiV) [Internet]. Atlanta:
a. CDC; 2024 [cited 2026 Jan 28]. Available from:
https://www.cdc.gov/vhf/nipah/index.html

[3] Chua KB. Nipah virus outbreak in Malaysia. *J Clin Virol*. 2003;26(3):265–275.

[4] Yob JM, Field H, Rashdi AM, Morrissy C, van der Heide B, Rota P, et al. Nipah virus infection in bats (Order Chiroptera) in peninsular Malaysia. *Emerg Infect Dis*.
a. 2001;7(3):439–441.

[5] Luby SP, Rahman M, Hossain MJ, Blum LS, Husain MM, Gurley ES, et al. Foodborne transmission of Nipah virus, Bangladesh. *Emerg Infect Dis*. 2006;12(12):1888–1894.

[6] Hossain MJ, Gurley ES, Montgomery JM, Bell M, Carroll DS, Hsu VP, et al. Clinical presentation of Nipah virus infection in Bangladesh. *Clin Infect Dis*. 2008;46(7):977– 984.

[7] Ang BSP, Lim TCC, Wang L. Nipah virus infection. *J Clin Microbiol*.
a. 2018;56(6):e01875-17.

[8] Clayton BA. Nipah virus: transmission of a zoonotic paramyxovirus. *Curr Opin Virol*.
a. 2017;22:97–104.

[9] Luby SP. The pandemic potential of Nipah virus. *Antiviral Res*. 2013;100(1):38–43.

[10] Luby SP, Rahman M, Hossain MJ, Blum LS, Husain MM, Gurley ES, et al. Foodborne transmission of Nipah virus, Bangladesh. *Emerg Infect Dis*. 2006;12(12):1888–1894.

[11] Tan CT, Goh KJ, Wong KT, Sarji SA, Chua KB, Chew NK, et al. Relapsed and lateonset Nipah encephalitis. *Ann Neurol*. 2002;51(6):703–708.

[12] Barker KL, ed. *The Making of the New International Version*. Grand Rapids (MI):
a. Zondervan; 1986.

[13] Metzger BM. *The Bible in Translation*. Grand Rapids (MI): Baker Academic; 2001.

[14] Gurley ES, Montgomery JM, Hossain MJ, et al. Person-to-person transmission of Nipah virus in a Bangladeshi community. **Emerg Infect Dis**. 2007;13(7):1031–1037.

[15] Mills JN, Alim ANM, Bunning ML, et al. Nipah virus infection in dogs, Malaysia, 1999. **Emerg Infect Dis**. 2009;15(6):950–952.

[16] Chua KB. Nipah virus outbreak in Malaysia. **J Clin Virol**. 2003;26(3):265–275.

[17] Parashar UD, Sunn LM, Ong F, et al. Case-control study of risk factors for human infection with Nipah virus, Malaysia. **J Infect Dis**. 2000;181(5):1755–1759.

[18] Chua KB. Nipah virus: a recently emergent deadly paramyxovirus. **Science**. 2000;288(5470):1432–1435.

[19] Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. **Nat Rev Microbiol**. 2006;4(1):23–35.

[20] [20]Chua KB, Bellini WJ, Rota PA, et al. Nipah virus: a recently emergent deadly paramyxovirus. **J Virol**. 2000;74(17):8127–8134.

[21] Parashar UD, Sunn LM, Ong F, et al. Case-control study of risk factors for human infection with Nipah virus, Malaysia. **J Infect Dis**. 2000;181(5):1755–1759.

[22] Hossain MJ, Gurley ES, Montgomery JM, et al. Clinical presentation of Nipah virus infection in Bangladesh. **Clin Infect Dis**. 2008;46(7):977–984.

[23] Luby SP, Gurley ES, Hossain MJ. Transmission of human infection with Nipah virus. **Clin Infect Dis**. 2009;49(11):1743–1748.

[24] Arunkumar G, Chandni R, Mourya DT, et al. Outbreak investigation of Nipah virus disease in Kerala, India, 2018. **J Infect Dis**. 2019;219(12):1867–1878.

[25] Luby SP, Rahman M, Hossain MJ, et al. Foodborne transmission of Nipah virus, Bangladesh. **Emerg Infect Dis**. 2006;12(12):1888–1894.

[26] Gurley ES, Montgomery JM, Hossain MJ, et al. Person-to-person transmission of Nipah virus in Bangladesh. **Emerg Infect Dis**. 2007;13(7):1031–1037.

[27] Homaira N, Rahman M, Hossain MJ, et al. Nipah virus outbreak with person-to-person transmission in a district of Bangladesh. **Epidemiol Infect**. 2010;138(11):1630–1636.

[28] Clayton BA. Nipah virus: transmission of a zoonotic paramyxovirus. **Curr Opin Virol**. 2017;22:97–104.

[29] Plowright RK, Eby P, Hudson PJ, et al. Ecological dynamics of emerging bat virus spillover. **Proc Biol Sci**. 2015;282(1798):20142124.

[30] Hahn MB, Epstein JH, Gurley ES, et al. Roosting behaviour and seasonal dynamics of Nipah virus in bats. **Epidemiol Infect**. 2014;142(10):2054–2063.

[31] Wacharapluesadee S, Boongird K, Wanghongsa S, et al. A longitudinal study of Nipah virus infection in bats in Thailand. **Emerg Infect Dis**. 2010;16(12):1993–1995.

[32] Reynes JM, Counor D, Ong S, et al. Nipah virus in bats, Cambodia. **Emerg Infect Dis**. 2005;11(7):1042–1047.

[33] Ching PKG, de los Reyes VC, Sucaldito MN, et al. Outbreak of henipavirus infection, Philippines, 2014. **Emerg Infect Dis**. 2015;21(2):328–331.

[34] Pulliam JRC, Epstein JH, Dushoff J, et al. Agricultural intensification and disease emergence. **Proc Natl Acad Sci USA**. 2012;109(10):3709–3714.

[35] Luby SP. The pandemic potential of Nipah virus. **Antiviral Res**. 2013;100(1):38–43.

[36] World Health Organization. Prioritizing diseases for research and development. **WHO Bull**. 2018.

[37] Lo MK, Rota PA. The emergence of Nipah virus, a highly pathogenic paramyxovirus.

a. **J Clin Virol**. 2008;43(4):396–400.

[38] Chua KB, Koh CL, Hooi PS, et al. Isolation of Nipah virus from Malaysian fruit bats. **Science**. 2002;288(5470):1432–1435.

[39] Yob JM, Field H, Rashdi AM, et al. Nipah virus infection in bats in peninsular Malaysia. **Emerg Infect Dis**. 2001;7(3):439–441.

[40] Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. **Nat Rev Microbiol**. 2006;4(1):23–35.

[41] Epstein JH, Prakash V, Smith CS, et al. Henipavirus infection in fruit bats, India. **Emerg Infect Dis**. 2008;14(8):1309–1311.

[42] Wacharapluesadee S, Boongird K, Wanghongsa S, et al. Longitudinal study of Nipah virus infection in *Pteropus* bats, Thailand. **Emerg Infect Dis**. 2010;16(12):1993–1995. 43) Reynes JM, Counor D, Ong S, et al. Nipah virus in bats, Cambodia. **Emerg Infect Dis**. 2005;11(7):1042–1047.

[43] Plowright RK, Eby P, Hudson PJ, et al. Ecological dynamics of emerging bat virus spillover. **Proc Biol Sci**. 2015;282(1798):20142124.

[44] Field H, Young P, Yob JM, et al. The natural history of Nipah virus in bats. **Microbes Infect**. 2001;3(4):307–314.

[45] Chua KB. Nipah virus outbreak in Malaysia. **J Clin Virol**. 2003;26(3):265–275.

[46] Middleton DJ, Morrissy CJ, van der Heide BM, et al. Experimental Nipah virus infection in pigs. **J Comp Pathol**. 2002;126(2–3):124–136.

[47] Eaton BT, Broder CC, Middleton D, Wang LF. Hendra and Nipah viruses: different and dangerous. **Nat Rev Microbiol**. 2006;4(1):23–35.

[48] Chua KB. Nipah virus outbreak in Malaysia. **J Clin Virol**. 2003;26(3):265–275.

[49] Chua KB, Koh CL, Hooi PS, et al. Isolation of Nipah virus from Malaysian fruit bats. **Science**. 2002;288(5470):1432–1435.

[50] Yob JM, Field H, Rashdi AM, et al. Nipah virus infection in bats in peninsular Malaysia. **Emerg Infect Dis**. 2001;7(3):439–441.

[51] Field H, Young P, Yob JM, et al. The natural history of Nipah virus in bats. **Microbes Infect**. 2001;3(4):307–314.

[52] Clayton BA. Nipah virus: transmission of a zoonotic paramyxovirus. **Curr Opin Virol**. 2017;22:97–104.

[53] Parashar UD, Sunn LM, Ong F, et al. Case-control study of risk factors for human infection with Nipah virus, Malaysia. **J Infect Dis**. 2000;181(5):1755–1759.

[54] Middleton DJ, Morrissy CJ, van der Heide BM, et al. Experimental Nipah virus infection in pigs. **J Comp Pathol**. 2002;126(2–3):124–136.

[55] Chua KB, Goh KJ, Wong KT, et al. Fatal encephalitis due to Nipah virus among pigfarmers in Malaysia. **Lancet**. 1999;354(9186):1257–1259.

[56] Luby SP, Rahman M, Hossain MJ, et al. Foodborne transmission of Nipah virus, Bangladesh. **Emerg Infect Dis**. 2006;12(12):1888–1894.

[57] Rahman MA, Hossain MJ, Sultana S, et al. Date palm sap linked to Nipah virus outbreak in Bangladesh. **Epidemiol Infect**. 2012;140(2):372–380.

[58] Hsu VP, Hossain MJ, Parashar UD, et al. Nipah virus encephalitis reemergence, Bangladesh. **Emerg Infect Dis**. 2004;10(12):2082–2087.

[59] Gurley ES, Montgomery JM, Hossain MJ, et al. Person-to-person transmission of Nipah virus in Bangladesh. **Emerg Infect Dis**. 2007;13(7):1031–1037.

[60] Homaira N, Rahman M, Hossain MJ, et al. Nipah virus outbreak with person-to-person transmission in Bangladesh. **Epidemiol Infect**. 2010;138(11):1630–1636.

[61] Arunkumar G, Chandni R, Mourya DT, et al. Outbreak investigation of Nipah virus disease in Kerala, India, 2018. **J Infect Dis**. 2019;219(12):1867–1878.

[62] Lo MK, Rota PA. The emergence of Nipah virus, a highly pathogenic paramyxovirus. **J Clin Virol**. 2008;43(4):396–400.

[63] Hahn MB, Epstein JH, Gurley ES, et al. Roosting behaviour and seasonal dynamics of Nipah virus transmission. **Epidemiol Infect**. 2014;142(10):2054–2063.

[64] Mills JN, Alim ANM, Bunning ML, et al. Nipah virus infection in dogs, Malaysia. **Emerg Infect Dis**. 2009;15(6):950–952.

[65] Plowright RK, Parrish CR, McCallum H, et al. Pathways to zoonotic spillover. **Nat Rev Microbiol**. 2017;15(8):502–510.

[66] Luby SP. The pandemic potential of Nipah virus. **Antiviral Res**. 2013;100(1):38–43.

[67] Wang LF, Yu M, Hansson E, et al. Molecular biology of Hendra and Nipah viruses. **Microbes Infect**. 2000;2(3):279–287.

[68] Rota PA, Lo MK. Nipah virus infection: molecular pathogenesis. **Curr Top Microbiol Immunol**. 2013;359:113–132.

[69] Bossart KN, Zhu Z, Middleton D, et al. Henipavirus pathogenesis and transmission.
a. **Antiviral Res**. 2009;83(2):146–158.

[70] Weingartl HM, Berhane Y, Czub M. Animal models of Nipah virus infection.
a. **Microbes Infect**. 2009;11(7):567–574.

[71] Aguilar HC, Lee B. Emerging paramyxoviruses: molecular mechanisms of entry. **Virology**. 2011;411(2):170–180.

[72] Bishop KA, Broder CC. Hendra and Nipah virus receptor usage and pathogenesis. **Cell Mol Life Sci**. 2008;65(5):831–843.

[73] Lee B, Ataman ZA. Modes of paramyxovirus fusion and cell entry. **Trends Microbiol**.
a. 2011;19(8):389–396.

[74] Maisner A, Neufeld J, Weingartl H. Organ tropism and pathology of Nipah virus. **J Pathol**. 2009;219(3):336–343.

[75] Rockx B, Brining D, Kramer J, et al. Clinical outcome and pathogenesis in nonhuman primates infected with Nipah virus. **PLoS One**. 2011;6(3):e18598.

[76] Escaffre O, Hill T, Ikegami T. Mechanisms of Nipah virus-induced vascular damage.
a. **Viruses**. 2020;12(2):227.

[77] Dups J, Middleton D, Long F, et al. Subclinical encephalitis in Nipah virus infection.

[78] **PLoS Negl Trop Dis**. 2012;6(4):e1642.

[79] Baseler L, de Wit E, Scott DP, et al. Nipah virus pathogenesis in the brain. **J Infect Dis**.
a. 2015;212(Suppl 2):S117–S126.

[80] Shieh WJ, Zaki SR. Pathology of emerging viral infections. **Curr Opin Infect Dis**.
a. 2006;19(3):239–245.

[81] Zaki SR, Shieh WJ. Nipah virus pathology and pathogenesis. **Semin Diagn Pathol**.
a. 2006;23(2):95–101.

[82] Clayton BA, Wang LF, Marsh GA. Henipaviruses: an updated review. **Virology**. 2013;443(2):238–248.

[83] DeBuysscher BL, Scott D, Marzi A, et al. Respiratory pathology of Nipah virus. **J Virol**. 2014;88(7):3816–3826.

[84] Prescott J, de Wit E, Falzarano D, et al. Immune responses to Nipah virus infection. **PLoS Pathog**. 2012;8(10):e1003067.

[85] Mathieu C, Pohl C, Szecsi J, et al. Interferon response in Nipah virus infection. **PLoS Pathog**. 2012;8(3):e1002441.

[86] Wong KT, Tan CT. Relapsing and late-onset Nipah encephalitis. **Neurol J Southeast Asia**. 2004;9:1–4.

[87] Munster VJ, Prescott JB, Bushmaker T, et al. Pathogenesis of emerging zoonotic viruses. **Annu Rev Pathol**. 2018;13:51–74.

[88] World Health Organization. Nipah virus: treatment and management guidelines. **WHO Bull**. 2019.

[89] Centers for Disease Control and Prevention. Nipah virus (NiV): clinical management. **CDC**. 2020.

[90] Arunkumar G, et al. Clinical management of Nipah virus infection. **Indian J Crit Care Med**. 2019;23(1):S29–S33.

[91] Goh KJ, Tan CT. Acute management of viral encephalitis. **Neurol Asia**. 2002;7:1–6.
92)Solomon T, Willison H. Infectious encephalitis: treatment strategies. **Lancet Neurol**.
a. 2003;2(12):709–718.
[92] Chong HT, Tan CT. Relapsed Nipah encephalitis and ribavirin therapy. **Neurology**.
a. 2003;60(1):170–172.
[93] Chong HT, Kamarulzaman A, Tan CT. Ribavirin treatment of Nipah virus infection.
a. **Clin Infect Dis**. 2001;32(2):306–312.
[94] Kumarasamy V, et al. Antiviral effects of ribavirin on Nipah virus. **Antiviral Res**.
a. 2003;58(1):39–45.
[95] Freiberg AN, et al. Lack of efficacy of ribavirin in experimental Nipah virus infection.
a. **J Infect Dis**. 2010;202(4):643–651.
[96] Chong HT, Kamarulzaman A, Tan CT. Ribavirin treatment of Nipah virus infection. **Clin Infect Dis**. 2001;32(2):306–312.

[97] Snell NJC. Ribavirin—current status of a broad spectrum antiviral agent. **Expert Opin Pharmacother**. 2001;2(8):1317–1324.

[98] Dawes BE, Kalveram B, Ikegami T, et al. Favipiravir protects against Nipah virus infection in Syrian hamsters. **Sci Rep**. 2018;8:7604.

[99] Smither SJ, Eastaugh LS, Steward JA, et al. Post-exposure efficacy of favipiravir against Nipah virus. **Antiviral Res**. 2014;110:1–6.

[100] Sheahan TP, Sims AC, Leist SR, et al. Broad-spectrum antiviral GS-5734 inhibits Nipah virus. **Sci Transl Med**. 2017;9(396):eaal3653.

[101] Jordan R, Gilliard G, Pham J, et al. Remdesivir activity against emerging viral pathogens. **Antiviral Res**. 2018;154:1–7.

[102] Bossart KN, Zhu Z, Middleton D, et al. A neutralizing human monoclonal antibody protects against lethal Nipah virus infection. **Proc Natl Acad Sci USA**. 2009;106(19):8131–8136.

[103] Mire CE, Geisbert JB, Agans KN, et al. Passive immunotherapy: successful treatment of Nipah virus infection. **Sci Transl Med**. 2016;8(332):332ra52.

[104] Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS and Nipah virus infection in vitro. **Virol J**. 2005;2:69.

[105] Park MS, Shaw ML, Munoz-Jordan J, et al. Interferon response in henipavirus infection. **J Virol**. 2003;77(16):8953–8962.

[106] Mathieu C, Porotto M, Figueira TN, et al. Fusion inhibitory lipopeptides prevent Nipah virus infection. **J Virol**. 2018;92(11):e00226-18.

[107] O'Keefe BR, Giomarelli B, Barnard DL, et al. Broad-spectrum antiviral activity of griffithsin. **Antimicrob Agents Chemother**. 2010;54(5):2185–2195.

[108] Pallister J, Middleton D, Wang LF, et al. Small molecule inhibitors targeting henipavirus entry. **Antiviral Res**. 2011;89(3):302–309.

[109] Burnouf T, Radosevich M. Treatment of emerging viral infections by convalescent plasma. **Transfus Apher Sci**. 2000;23(3):219–226.

[110] World Health Organization. Nipah virus: prevention and control strategies.

[111] **WHO Bull**. 2020.

[112] Centers for Disease Control and Prevention. Nipah virus (NiV): prevention. **CDC**. 2021.

[113] Luby SP, Khan MSU, Hossain MJ, et al. Foodborne transmission of Nipah virus: prevention strategies. **Emerg Infect Dis**. 2009;15(8):1222–1228.

[114] Nahar N, Mondal UK, Hossain MJ, et al. Reducing exposure to bat-borne Nipah virus using bamboo skirts. **EcoHealth**. 2010;7(3):363–372.

[115] Khan MSU, Hossain J, Gurley ES, et al. Use of interventions to prevent Nipah virus transmission via date palm sap. **PLoS One**. 2012;7(8):e42689.

[116] Gurley ES, Hegde ST, Hossain MJ, et al. Behavioral interventions to prevent Nipah virus transmission. **Am J Trop Med Hyg**. 2017;96(4):1–7.

[117] Pulliam JRC, Epstein JH, Dushoff J, et al. Agricultural intensification and Nipah virus emergence. **Proc Natl Acad Sci USA**. 2012;109(10):3709–3714.

[118] Field HE. Biosecurity and prevention of henipavirus spillover. **Microbiol Aust**. 2016;37(3):108–111.

[119] Hossain MJ, Gurley ES, Montgomery JM, et al. Surveillance and outbreak detection of Nipah virus. **Clin Infect Dis**. 2008;46(7):977–984.

[120] Homaira N, Rahman M, Hossain MJ, et al. Nosocomial transmission of Nipah virus and infection control. **Epidemiol Infect**. 2010;138(11):1630–1636.

[121] Arunkumar G, et al. Containment of Nipah virus outbreak in Kerala, India. **Indian J Med Res**. 2019;149(2):147–153.

[122] Chadha MS, Comer JA, Lowe L, et al. Nipah virus outbreak investigation and contact tracing. **Emerg Infect Dis**. 2006;12(2):235–240.

[123] WHO Regional Office for South-East Asia. Infection prevention and control for Nipah virus. **SEARO Tech Rep**. 2018.

[124] World Health Organization. Prioritizing diseases for research and development.
[125] **WHO R&D Blueprint**. 2018.
[126] Luby SP. One Health approaches to prevention of Nipah virus. **Philos Trans R Soc Lond B Biol Sci**. 2013;368(1623):20120198.

[127] World Health Organization. Nipah virus: diagnostic recommendations. **WHO Bull**. 2017.

[128] Centers for Disease Control and Prevention. Laboratory testing for Nipah virus. **CDC**. 2022.

[129] Chadha MS, Comer JA, Lowe L, et al. Nipah virus-associated encephalitis outbreak. **Emerg Infect Dis**. 2006;12(2):235–240.

[130] Arunkumar G, et al. Clinical features and diagnosis of Nipah virus infection in India. **Indian J Med Res**. 2019;149(2):147–153.

[131] Guillaume V, Lefeuvre A, Faure C, et al. Specific detection of Nipah virus using RT-PCR. **J Virol Methods**. 2004;120(2):229–237.

[132] Wacharapluesadee S, Hemachudha T. Duplex RT-PCR for detection of Nipah virus. **J Clin Virol**. 2007;39(1):59–64.

[133] Daniels P, Ksiazek T, Eaton BT. Laboratory diagnosis of Nipah virus infection. **Microbes Infect**. 2001;3(4):289–295.

[134] Towner JS, Rollin PE, Bausch DG, et al. Rapid diagnosis of emerging viral diseases in BSL-4 laboratories. **J Virol**. 2004;78(8):4330–4336.

[135] Ramasundram V, Tan CT, Chua KB, et al. Serological diagnosis of Nipah virus infection. **J Med Virol**. 2000;61(3):293–298.

[136] Hossain MJ, Gurley ES, Montgomery JM, et al. Serologic evidence of Nipah virus infection. **Clin Infect Dis**. 2008;46(7):977–984.

[137] Ksiazek TG, Rota PA, Rollin PE. Serological tests for henipavirus diagnosis. **J Infect Dis**. 2011;204(Suppl 3):S979–S985.

[138] Zaki SR, Shieh WJ. Immunohistochemical diagnosis of Nipah virus. **Semin Diagn Pathol**. 2006;23(2):95–101.

[139] Lim CC, Sitoh YY, Hui F, et al. MRI features of Nipah virus encephalitis. **Radiology**. 2000;217(3):790–795.

[140] Gurley ES, Hegde ST, Hossain MJ, et al. Surveillance and diagnosis during Nipah outbreaks. **Emerg Infect Dis**. 2017;23(3):388–396.

[141] WHO Regional Office for South-East Asia. Laboratory diagnosis of Nipah virus infection. **SEARO Tech Rep**. 2018.

[142] Wang LF, Anderson DE. Viruses in bats and potential spillover to humans.
[143] **Curr Opin Virol**. 2019;34:79–89.
[144] Munster VJ, Bausch DG, de Wit E, et al. Outbreaks in a rapidly changing central Africa. **Trends Microbiol**. 2018;26(7):568–580.

[145] Field HE, Epstein JH, Henipavirus ecology. **Curr Top Microbiol Immunol**. 2013;359:231–256.

[146] Luby SP, Gurley ES, Hossain MJ. Transmission dynamics of Nipah virus. **Clin Infect Dis**. 2009;49(11):1743–1748.

[147] Arankalle VA, Bandyopadhyay BT, Ramdasi AY, et al. Genomic characterization of Nipah virus, India. **Emerg Infect Dis**. 2011;17(5):907–909.

[148] Plowright RK, Eby P, Hudson PJ, et al. Land use change and zoonotic disease emergence. **Philos Trans R Soc Lond B Biol Sci**. 2015;370(1665):20140170.

[149] Daszak P, Cunningham AA, Hyatt AD. Emerging infectious diseases of wildlife. **Science**. 2000;287(5452):443–449.

[150] Lim CC, Sitoh YY. Imaging findings in viral encephalitis. **Eur Radiol**. 2002;12(9):2170–2175.

[151] Towner JS, Sealy TK, Khristova ML, et al. Detection of emerging zoonotic viruses. **PLoS Pathog**. 2008;4(10):e1000102.

[152] Broder CC, Xu K, Nikolov DB, et al. Therapeutics and vaccines for henipaviruses. **Curr Opin Virol**. 2013;3(3):264–271.

[153] Mire CE, Geisbert TW. Passive immunotherapy for emerging viral diseases. **Viruses**. 2014;6(8):3148–3167.